Blum Robert I 4

What Happened
Robert I. Blum, President & CEO and a director of Cytokinetics, sold 7,500 shares in an open-market transaction on June 15, 2026. The shares were disposed at $70.46 each, generating proceeds of $528,450. This was a sale (not a purchase or option exercise), which is often a routine liquidity event rather than a direct signal of company fundamentals.

Key Details

• Transaction date: 2026-06-15
• Transaction type/code: Open-market sale (S)
• Shares sold: 7,500 at $70.46 per share
• Total proceeds: $528,450
• Shares owned after transaction: Not specified in the provided filing excerpt
• Footnotes: F1 and F2 indicate shares are held by The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust, respectively
• Filing timeliness: Reported on 2026-06-15 (same day), which appears timely

Context
Sales by executives can be for many reasons (diversification, taxes, personal needs) and are not by themselves definitive indicators of company prospects. Because this was an open-market sale and involved shares held via irrevocable trusts (per footnotes), treat this as a routine insider disposition unless further filings or company developments provide additional context.